Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery
International Journal of Molecular Sciences · 04.08.2026 · 27 (15) · 6992
DOI: 10.3390/ijms27156992 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.08.2026. Verfasst von Elisa Uliassi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum-Università di Bologna, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Neoplasms, Drug Discovery, Antineoplastic Agents. Die Arbeit nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rizzoli Orthopaedic Institute, Italian Ministry of Health.
Abstract (Originalsprache)
RNA-binding proteins (RBPs) remain underexplored as small-molecule targets, although their dysregulation contributes to numerous human diseases, including cancer. RBPs are key regulators of post-transcriptional gene expression, controlling multiple stages of RNA metabolism. Among them, insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is an oncofetal RBP that is highly expressed during embryonic development, largely absent in adult tissues, and re-expressed in multiple malignancies. A growing body of evidence supports IGF2BP3 as a diagnostic and prognostic biomarker and a potent oncogenic driver across tumor types, underscoring its potential as a therapeutic target. However, the development of effective IGF2BP3-targeting compounds remains in its early stages. In this review, we first describe the structural organization of IGF2BP3, the molecular basis of RNA recognition, and the mechanisms underlying its dysregulation across human cancers. We then discuss emerging therapeutic approaches, including direct inhibition of IGF2BP3–RNA interactions and indirect strategies that rewire IGF2BP3 expression or activity through epigenetic, epitranscriptomic, and signaling pathways. By critically highlighting the opportunities and limitations of these approaches and their impact on cancer progression, we provide an integrated perspective combining structural biology, medicinal chemistry, and cancer biology to support the development of next-generation IGF2BP3-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum-Università di Bologna, 40126 Bologna, Italy.
- Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
ORCID-Profile: Elisa Uliassi, Maria Laura Bolognesi, Katia Scotlandi, Caterina Mancarella
Förderung
- Rizzoli Orthopaedic Institute
- Italian Ministry of Health
Zitieren
APA
Uliassi, E., Bolognesi, M. L., Scotlandi, K., & Mancarella, C. (2026). Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery. International Journal of Molecular Sciences, 27(15), 6992. https://doi.org/10.3390/ijms27156992
Vancouver
Uliassi E, Bolognesi ML, Scotlandi K, Mancarella C. Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery. International Journal of Molecular Sciences. 2026;27(15):6992. doi:10.3390/ijms27156992
BibTeX
@article{Uliassi2026,
author = {Uliassi, Elisa and Bolognesi, Maria Laura and Scotlandi, Katia and Mancarella, Caterina},
title = {Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {6992},
doi = {10.3390/ijms27156992}
}
EUVIMED